BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Universidad Complutense de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (24)
2024
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
Cancers, Vol. 15, Núm. 12
2022
-
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 968-980
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
2021
-
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336
-
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group
British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC
Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Blood Advances, Vol. 4, Núm. 23, pp. 6023-6033
2019
-
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759
-
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Leukemia
-
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811
2018
-
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility
Haematologica, Vol. 103, Núm. 5, pp. 880-889
2017
-
Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 474-486
2016
-
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
Hematological Oncology, Vol. 34, Núm. 2, pp. 84-92